Predicting distant dissemination in patients with early breast cancer

References

• Sarrazin D, Dewar JD, Arriagada R, Benhamou S, Benhamou E, Lasser P, et al. Conservative management of breast cancer. Br J Surg 1986; 73: 604–6
   PubMedGoogle Scholar
• Lê MG, Arriagada R, Spielmann M, Guinebretière JM, Rochard F. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer 2002; 94: 2813–20
   PubMed Web of Science ®Google Scholar
• Arriagada R, Lê MG, Dunant A, Tubiana M, Contesso G. Twenty-five years of follow-up in operable breast cancer: Relationship between clinicopathological factors and death risk in each 5-year period. Cancer 2006; 106: 743–50
   PubMedGoogle Scholar
• Arriagada R, Rutqvist LE, Skoog L, Johansson H. Prognostic factors and natural history in lymph nodes-negative breast cancer patients. Breast Cancer Res Treat 1992; 21: 101–9
   PubMed Web of Science ®Google Scholar
• Spyratos F, Martin PM, Hacène K, Romain S, Andrieu C, Ferrero-Pous M, et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992; 84: 1266–72
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817–26
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999–2009
   PubMed Web of Science ®Google Scholar
• Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: Updated overview of the Swedish randomised trials. Lancet 2002; 359: 909–19
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366:2087–106.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717.
   PubMed Web of Science ®Google Scholar
• Arriagada R, Rutqvist LE, Mattsson A, Kramar A, Rotstein S. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 1995; 13: 2869–78
   PubMed Web of Science ®Google Scholar
• Koscielny S, Tubiana M, Lê MG, Valleron AJ, Mouriesse H, Contesso G, et al. Breast cancer, relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 1984; 49: 709–15
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343–6
   PubMedGoogle Scholar
• Wrange Ö, Nordenskjöld B, Gustafsson JA. Cytosol estradiol receptor in human mammary carcinoma. An assay based on isolectric focusing in polyacrylamide gel. Anal Biochem 1978; 85: 416–21
   Web of Science ®Google Scholar
• Burton KA. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of DNA. Biochem J 1956; 62: 315–22
   PubMed Web of Science ®Google Scholar
• Arriagada R, Mouriesse H, Sarrazin D, Clark RM, Deboer G. Radiotherapy alone in breast cancer. I. Analysis of tumor parameters, tumor dose and local control: The experience of the Gustave-Roussy Institute and The Princess Margaret Hospital. Int J Radiat Oncol Biol Phys 1985; 11: 1751–7
   PubMed Web of Science ®Google Scholar
• Byar DP. Analysis of survival data: Cox and Weibull models with covariates. Statistics in Medical Research, V Miké, KE Stanley. J. Wiley, New York 1982; 365–401
   Google Scholar
• Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology 1987; 7: 1346–58
   PubMed Web of Science ®Google Scholar
• Gelman R, Gelber R, Henderson IC, Coleman CN, Harris JR. Improved methodology for analysing local and distant recurrence. J Clin Oncol 1990; 8: 548–55
   PubMed Web of Science ®Google Scholar
• Kramar A, Pejovic MH, Chassagne DA. A method of analysis taking into account competing events: Application to the study of digestive complications following irradiation for cervical cancer. Stat Med 1987; 6: 785–94
   PubMedGoogle Scholar
• Arriagada R, Rutqvist LE, Kramar A, Johansson H. Competing risks determining event-free survival in early breast cancer. Br J Cancer 1992; 66: 951–7
   PubMedGoogle Scholar
• UICC. TNM: Classification of malignant tumors. 3rd ed. Geneva: 1979.
   Google Scholar
• Joensuu H, Pylkkänen L, Toikkanen S. Long-term survival in node-positive breast cancer treated by locoregional therapy alone. Br J Cancer 1998; 78: 795–9
   PubMedGoogle Scholar
• Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1NoMo) and stage II (T1N1Mo) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; 7: 1239–51
   PubMed Web of Science ®Google Scholar
• Sigurdsson H, Baldetorp B, Borg GA, Fernö M, Killander D, Olsson H. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 1045–53
   PubMed Web of Science ®Google Scholar
• Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D, Rouesse J. The importance of histologic grade in long-term prognosis of breast cancer. A study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987; 5: 1378–86
   PubMed Web of Science ®Google Scholar
• Verschraegen C, Vinh-Hung V, Cserni G, Gordon R, Royce ME, Vlastos G, et al. Modeling the effect of tumor size in early breast cancer. Ann Surg 2005; 241: 309–18
   PubMed Web of Science ®Google Scholar
• Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966–78
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569–83
   PubMed Web of Science ®Google Scholar
• Von Rosen A, Rutqvist LE, Carstensen J, Fallenius A, Skoog L, Auer G. Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content. Breast Cancer Res Treat 1989; 13: 23–32
   PubMed Web of Science ®Google Scholar
• McGuire WL, Tandon AK, Allred DC, Chamness C, Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients. JNCI 1990; 82: 1006–15
   PubMed Web of Science ®Google Scholar
• Hofvind S, Sørum R, Thoresen S. Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. Acta Oncol 2007; 1–7.
   Google Scholar
• Koscielny S, Tubiana M. The link between local recurrences and distant metastases in human breast cancer. Int J Radiat Oncol Biol Phys 1999; 43: 11–24
   PubMedGoogle Scholar
• Wilking N, Rutqvist LE, Carstensen J, Mattsson A, Skoog L, and participating members of the Stockholm Breast Cancer Study Group. Prognosis significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Acta Oncol 1992;31:29–36.
   PubMed Web of Science ®Google Scholar
• Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312: 1604–8
   PubMed Web of Science ®Google Scholar
• Atahan IL, Yildiz F, Ozygit G, Sari S, Gurkaynak M, Selek U, et al Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer. Acta Oncol 2007:1–7.
   Google Scholar
• Joensuu H, Toikkanen S, Klemi PJ. DNA Index and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma. Cancer 1990; 66: 331–40
   PubMed Web of Science ®Google Scholar
• Lonn U, Lonn S, Nilsson B, Stenkvist B. Breast cancer: Prognostic significance of c-erb B2 and Int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features. Breast Cancer Res Treat 1994; 29: 237–45
   PubMed Web of Science ®Google Scholar
• Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study. Clin Cancer Res 2003; 9: 923–30
   PubMed Web of Science ®Google Scholar
• Joensuu H, Lehtimäki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004; 292: 1064–73
   PubMedGoogle Scholar
• Lundin J, Lehtimäki T, Lundin M, Holli K, Elomaa L, Turpeenniemi-Hujanen T, et al. Generalisability of survival estimates for patients with breast cancer – A comparison across two population-based series. Eur J Cancer 2006; 42: 3228–35
   PubMedGoogle Scholar
• Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet 2005; 365: 488–92
   PubMed Web of Science ®Google Scholar
• Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726–34
   PubMed Web of Science ®Google Scholar